MedX Health Launches Study of Teledermatology Screening Platform

MedX Health Corp. is rolling out an inaugural study of its DermSecure Screening Platform in Turkey.

The six-month trial will occur at three university hospitals and enroll roughly 300 patients. After the study is completed, MedX and its distributor Makromed/Arhan Global A.Ş will supply DermSecure to clinics, pharmacies and insurance companies throughout Turkey. “This inaugural clinical trial marks an important first step in establishing our technology and path to reimbursement in medical facilities across Turkey, a market of more than 80 million people. It’s a significant milestone in our global commercialization strategy,” MedX CEO Sylvain Desjeans said.

This study builds on MedX’s existing European commercialization pilots in the Netherlands and Italy, as part of the company’s global commercialization strategy. The study will be overseen by Turkish dermatologist, Dr. Emel Erdal Çalikoğlu, a professor of Dermatology at Dokuz Eylül University in İzmir, Turkey. The clinical trial will also include Kocaeli University, led by professor of Dermatology Dr. Dilek Bayramgürler, as well as Bursa Uludağ University, led by professor of Dermatology Dr. Emel Bülbül Başkan and associate professor Dr. Serkan Yazici. 
 
“There are types of melanoma tumors which we can more effectively treat by early detection. As such, I strongly believe that MedX’s SIAscopy and DermSecure can help our fight against melanoma,” said Erdal Çalikoğlu. “We look forward to seeing the results of this study and bringing MedX’s world-class teledermatology device and platform to those dermatology patients who need it most. Using MedX’s innovative technology should become part of dermatologists’ daily practice.”
 
Teledermatology is a subspeciality of dermatology that offers safe and effective virtual care—patient screening and assessment—eliminating the need for in-person appointments with a dermatologist. Unlike other teledermatology screening tools available, MedX’s DermSecure Screening Platform features high-resolution image capture technology for moles, lesions and other skin conditions; providing a complete, virtual dermatological assessment by a certified dermatologist within just 72 hours.
 
MedX’s telemedicine platform allows health-care practitioners to quickly and accurately assess suspicious moles, lesions and other skin conditions via its image capture technology, SIAscopy, and its secure, cloud-based patient management system, DermSecure, which transmits and stores patient data throughout the assessment process. MedX’s SIAscopy is the only technology that captures five images, including four spectrophotometric images 2mm below the skin’s surface. 

“Working with such notable dermatologists as Dr. Çalikoğlu means securing a strong, credible foothold with the dermatology community in the Turkish market. We eagerly anticipate the results of the study, and the positive impact it will have on skin health patients across the country,” said Chantal Ward, MedX director, Medical Affairs.
 
“With the clinical trial and distribution agreement with Makromed, this market shows incredible growth potential for MedX— both in terms of increasing patient access and establishing reimbursement through the Turkish healthcare system. We look forward to leveraging this growth opportunity as one of many in Europe and beyond,” said Naman Demaghlatrous, MedX managing director of Europe, Middle East and Africa. 
 
MedX, headquartered in Ontario, Canada, is focused on skin health with its SIAscopy on DermSecure telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS, SIMSYS, and MoleMate, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS, SIMSYS, and MoleMate include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the United States, Australia, New Zealand, the European Union, Brazil, and Turkey.